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In a prospective infant cohort, 21 infants developed Plasmo-
dium vivax malaria during their ﬁrst year. Twelve of their
mothers also had vivax malaria in the corresponding preg-
nancies or postpartum period. The genotypes of the maternal
andinfantinfectionswerealldifferent.Eightofthe12mothers
and 9 of the 21 infants had recurrent infections. Relapse
parasite genotypes were different to the initial infection in 13
of 20 (65%) mothers compared with 5 of 24 (21%) infants
(P 5 .02). The ﬁrst P. vivax relapses of life are usually genet-
ically homologous, whereas relapse in adults may result from
activation of heterologous latent hypnozoites acquired from
previous inoculations.
Plasmodium vivax is a major cause of morbidity in Asia and the
Americas. In tropical areas, a high proportion of acute vivax
malaria infections are followed soon afterward by a relapse if
radical treatment with primaquine is not given [1–3]. The
interval to the ﬁrst relapse averages 3 weeks if rapidly elimi-
nated drugs are given for acute treatment and 7 weeks with
slowly eliminated drugs. There is also a high rate of P. vivax
recurrence following falciparum malaria (30%–50%) [4, 5].
The intervals between acute vivax malaria and the ﬁrst relapse
and between falciparum malaria and the subsequent vivax
episode are very similar, suggesting that this too is a relapse. The
relapse patterns in malaria-naive volunteers infected with the
Chesson strain of P. vivax [6] and the rhesus monkeys infected
with Plasmodiumcynomolgi[7]areverysimilartothoseobserved
in natural infections. It had therefore been assumed that vivax
relapses would derive from the same infection that caused the
acute illness. Three studiesdone in patients in Thailand [8],
another in Australian soldiers who acquired vivax malaria in East
Timor [9], and a third more recent investigation in Colombia
[10]dall showed this was not the case. Approximately two-
thirds of the relapses in these studies derived from parasites that
could not be detected in the initial acute infection. There were
several possible explanations. Perhaps there was suppression of
some genotypes in a mixed-genotype infection or signiﬁcant
differences in the incubation periods of inoculated parasite
genotype mixtures, or, alternatively, the relapses derived from
a different previous mosquito inoculation. We reasoned that
although a primary asymptomatic infection can occur in
infancy, this is relatively unusual [11], so there should generally
be no hypnozoites from previous infections in the ﬁrst
P. vivax infection of life. We therefore genotyped the ﬁrst
P. vivax infection of life and subsequent recurrences in
a cohort of infants followed prospectivelyinamalaria-endemic
area on the northwestern border of Thailand.
METHODS
The study took place from November 2007 until January 2011
in the Shoklo Malaria Research Unit (SMRU) clinics on the
northwestern border of Thailand, an area of low and seasonal
malaria transmission (entomological inoculation rate for
P. vivax ,0.5 per person per year). Mothers were enrolled after
giving written consent in a prospective study to investigate the
effects of malaria in pregnancy, postpartum, and in infancy.
From enrollment until 12 weeks after delivery, weekly blood
smears and polymerase chain reaction (PCR) spots were taken
from the mothers. Their infants were sampled every 2 weeks,
and after 3 months every 4 weeks until 1 year of age.
Plasmodium vivax was diagnosed by microscopy and treated
in mothers and infants with chloroquine (25 mg base/kg;
Government Pharmaceutical Organisation [GPO], Thailand).
Radical treatment is not given routinely in this population.
However, if an infant had .2 recurrent infections of P. vivax,
directly observed treatment with primaquine (0.5 mg base/kg
for 14 days) was given after the infant was tested G6PD
negative. Primaquine was not given to the mothers during
pregnancy.
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Laboratory
Blood smears (thin and thick ﬁlms) were stained with Giemsa
and read for 200 ﬁelds before declaring a negative. Blood spots
for PCR analysis were collected on Whatman ﬁlter paper and
stored in plastic bags with silica gel.
Genotyping
For P. vivax genotyping, PCR ampliﬁcation of 8 microsatellite
markers was performed following previously described proto-
cols[12, 13]. The microsatellite markers were PV3.27,PV3.502,
PV ms1, PV ms5, PV ms 6, PV ms7, PV ms8, and PV ms16.
Measurement of allele length and quantiﬁcation of peak heights
were performed using an ABI 3130 Genetic Analyzer and Gen-
eMapper software version 4.0 (Applied Biosystems). The sam-
ples were reanalyzed when ampliﬁcation was poor for particular
loci (maximum peak height ,200 ﬂuorescence units). Samples
were scored as indeterminate if $5 markers (loci) failed to
amplify on repeat testing. Blood stage malaria parasites are
haploid, and mixed infection with $2 or more haploid clones is
frequent. The presence of $1 additional alleles at a locus could
result either from a mixed-genotype infection or mutation
(strand slippage) of the microsatellite repeat during asexual di-
vision within the blood stage infection producing a mixture.
We scored multiple alleles per locus if minor peaks were more
than half of the height of the predominant allele present for each
locus. To estimate the likelihood of strand slippage during the
ampliﬁcation process (ie, as an ex vivo artifact) we conducted
ampliﬁcations of 6 microsatellite loci for 5 different samples
containing a single P. vivax genotype on 10 separate occasions.
Statistical Analysis
The individual frequency distribution of each allele at each mi-
crosatellite locus was calculated, and the probabilities of identical
alleles occurring at each locus in 2 independent parasite isolates
was thereby derived. The probability of ﬁnding a complete match
at each locus for the most common genotype was 8.45 3 10
26,
and the probability of ﬁnding a match at 7 of 8 loci for the most
common genotype was 5.63 3 10
25. When comparing parasite
genotypes, some parasites were observed that were identical
at $6 loci and showed either a mixture of 2 adjacent micro-
satellite alelles at 1 locus (one of which was present in the
primary infection) or had alleles that differed by 1 tandem
repeat at the remaining 1 or 2 loci. These were considered





of 12 (range, 0–12) months. Over the 39-month study period,
7 infants had P. falciparum and 23 infants had 51 P. vivax
infections, with a median of 2.5 (range, 1–6) episodes per in-
fected infant. The median age at ﬁrst vivax malaria was 31
(range, 4–51) weeks. The median age at ﬁrst infection in the
9 infants whose infections recurred was 26 (range, 4–40) weeks
compared with 36 (range, 4–51) weeks in the 11 infants
Table 1. Plasmodium vivax Recurrences in Mothers and Infants
Mothers (n 5 12) Infants (n 5 21) P Value
No. of recurrent Plasmodium vivax infections 8 9 ..2
No. of recurrences documented, median (range) 2.5 (1–5) 2.5 (1–6) ..2
Interval of recurrence, days, median (range) 45 (21–82) 37 (11–168)
First recurrence similar to initial infection 2/8 A 7/9 A .02
1 indeterminate 1 indeterminate
Second recurrence similar to initial infection 1/6 A 3/6 A ..1
1 indeterminate 1/6 B
Third recurrence similar to initial infection 1/4 B 2/5 A .5
1 indeterminate 1 indeterminate
Fourth recurrence similar to initial infection 0/1 2/2 A .3
Fifth recurrence similar to initial infection 0/1 1/1 B .5
Sixth recurrence similar to initial infection . 1/1 A .
Proportion of recurrences that were genotypically similar 4/20 17/24 .02
3 indeterminate 2 indeterminate
In genotypically different recurrences, median proportion of different alleles (range) 80% (50%–100%) 63% (57%–86%) .008
Criteria for interpretation: A 5 0, 1 marker (loci) different or 2 markers (loci) different with #1 possible stepwise mutation; B 5 3 markers (loci) different but
#1 repeat unit, different with #1 possible stepwise mutation; indeterminate: $5 markers (loci) failed to amplify.
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infections, 40 (78%) were symptomatic, presenting with
fever, and the remaining 11 were detected actively in routine
follow-up. Twelve of the infants’ mothers had vivax malaria
in the corresponding pregnancies or postpartum period.
Within each mother-infant pairing, the median number of
episodes in the mothers was 2.5 (range, 1–5). Blood spots for
PCR were available from 8 of these mothers who experienced
20 recurrent infections. All patients responded initially to
chloroquine. Four infants received radical curative treatment
with primaquine after they had experienced their second
recurrent infection.
Genotyping Results
Of the 23 infants, 21 provided blood spots for genotyping, of
whom 9 had recurrent infections (in total, 24 recurrences).
Mixed-genotype infections were found in 55% of the mothers
and 43% of infants. The genotypes of the maternal and cor-
responding infant infections were different in all cases. Pla-
cental samples taken during delivery (n 5 5) were negative by
microscopy. The genotypes were different to the initial in-
fection for 13 of the 20 recurrences in the 8 mothers, were the
same in 4 (in 1 mother the primary infection and 2 subsequent
recurrences were similar), and 3 pairs were indeterminate
(Figure 1). In contrast, in the infants, most of the presumed
relapses were of similar genotypes to the primary infection.
Only 5 of 24 recurrences in the infants were with clearly dif-
ferent genotypes (Table 1). The relative risk of having a relapse
caused by a different genotype in mothers compared with their
infants, in satisfactorily genotyped infections, was 3.5 (95%
conﬁdence interval [CI],1.6–8.0; P 5 .02).
Interrecurrence Intervals
In the mothers the median interrecurrence interval was 45
(range, 21–82) days. The intervals between genetically homol-
ogous (median, 45 days; range, 21–82 days) and heterologous
recurrences (median, 49 days; range, 21–56 days) were similar.
In the infants, the median interrecurrence interval was 37
(range, 11–168) days, and the intervals were also not different
between genetically homologous (median, 35 days; range, 11–
168 days) and heterologous recurrences (median, 41 days; range,
30–73 days). All recurrences in the infants with intervals ,5w e e k s
(n 5 8) were genetically homologous. Of the 18 homologous
genotype recurrences, 11 occurred following an interval of
28–44 days. None of the 7 P. falciparum infections were followed
by P. vivax within 3 months.
DISCUSSION
This small series suggests that the pattern of P. vivax genotypes
in pregnant women with presumed relapses of vivax malaria is
similar to that observed previously in Thailand [8]. The ma-
jority were with genotypes different to those of the initial
infection (which too may have been a relapse). The pattern was
different in their infants. The presumed relapses that followed
the ﬁrst vivax malaria episode of life were usually with geno-
types similar to those that caused the initial infection. These
studies were conducted in an endemic area so reinfection
cannot be excluded, although transmission intensity in this
area was low (3.7 infections per 100 person-years in infancy).
Reinfection probably caused some or all of the 5 genetically
heterologous recurrences in the infants but cannot account for
the similarity of most recurrences (72%). Chloroquine efﬁcacy
is declining in the area but still provides 28-day cure rates of
88%, so recrudescence cannot be excluded. One infant had
a second P. vivax recurrence only 11 days after the ﬁrst re-
currence (61 days after the primary infection); the ﬁrst re-
currence was heterologous, but the second was genetically
identical to the initial infection, so it was not a recrudescence of
the preceding infection but a relapse of the primary infection.
Most initial recurrences were 1–2 months following treatment,
the time when most relapses occur following chloroquine
treatment in this area [1–3].
Figure 1. TemporalpatternandgenotypingofrecurrencesofPlasmodium
vivax malaria in 8 mothers (A) and 9 infants (B). Each number on the y-axis
represents a patient. Filled circles denote the initial infection. An open
circle represents a genetically homologous recurrence, and a black diamond
represents a genetically heterologous recurrence. Recurrences where
genotyping was indeterminate (2 in infants, 3 in mothers) are not shown.
One mother's sole relapse was indeterminate.
682 d JID 2012:205 (15 February) d BRIEF REPORTThe assessment of genotypic similarity from this micro-
satellite typing is imprecise. Recombination between genetically
different parasites in the anopheline mosquito vector results in
related progeny, which may become very highly related through
subsequent interbreeding in serial passage. Microsatellite mu-
tation rate estimates have not been made for P. vivax, but for




24)[ 14]. These usually result in single-
pair increases or decreases in the number of tandem repeats at
each locus, termed ‘‘slippage.’’ Therefore, infections may com-
prise closely related genotypes, and different genotypes may
emerge during the course of infection. Infections that have a
common origin may, therefore, differ at $1 loci. Slippage might
also occur as an ex vivo artifact during the PCR ampliﬁcation,
but repeat testing in this study suggested that this did not occur
frequently. We did not attempt to distinguish between these
various sources of genetic difference because our primary ob-
jective was to distinguish between a single or separate parasite
inoculations. We therefore included together parasites with
1 or 2 different alleles as originating from the same inoculation
because it was statistically highly improbable that they origi-
nated separately.
The parasite genotypes causing maternal and corresponding
infant infections were different in each case, which suggests that
there was no congenital transmission. Blood transfer of infec-
tion should give similar genotypes in donor and recipient. These
results suggest that a substantial proportion of relapses in adult
patients do not derive from the mosquito inoculation of para-
sites that caused the preceding infection. In contrast, the infants
had similar genotypes in their relapses, suggesting that their
relapses did derive from the same inoculation of parasites that
caused the initial infection. Because there is no reason why
mosquito inoculation should differ substantially between adults
and infants, the most likely explanation for this marked differ-
ence is activation of heterologous latent hypnozoites in adults
from previous inoculations. More complex explanations in-
volving inoculation of multiple genotypes with differences in
incubation periods or signaling between genotypes are un-
necessary. These data may also help explain the origin of the
presumedP.vivaxrelapsesthatfollowtreatmentofP.falciparum
infections in between one-third and one-half of patients with
falciparummalariainthisregion[4,5].Simultaneousinoculation
seems unlikely to account for these because the anopheline
vectors rarely carry both parasite species [15]. The P. vivax
infections that follow falciparum malaria could result from
activation of hypnozoites derived from previous inoculations.
Interestingly, none of the 7 P. falciparum infections in infants
were followed by P. vivax. Taken together, all the data point to
the accumulation of latent hypnozoites in a signiﬁcant pro-
portion of the population in malaria-endemic areas of Asia.
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